Veristat continues to support Antibe Therapeutics, a biotech company with a drug platform of game-changing therapeutics in pain and inflammation, as they receive approval to initiate the second part of their phase 2B dose-ranging, efficacy study for ATB-346.
Expanding Its Clinical Operations and Biometrics Teams Dedicated to Emerging, Small and Mid-Sized Biopharma
Veristat Congratulates Agios on the FDA Approval of TIBSOVO®
August 16, 2018
The First Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
SOUTHBOROUGH, MA – August 16, 2018 – Veristat, a full service Clinical Research Organization (CRO), congratulates Agios on the recent FDA approval of TIBSOVO® (ivosidenib) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA approved test.
Veristat’s Strategic Guidance Contributes to Successful Approval of Aegerion’s Novel Drug Juxtapid